Koios DS
Koios Medical, Inc.Product specifications |
Information source:
Vendor
Last updated: Oct. 24, 2023 |
General | |
---|---|
Product name | Koios DS |
Company | Koios Medical, Inc. |
Subspeciality | Breast, Thyroid |
Modality | Ultrasound |
Disease targeted | Breast cancer, thyroid cancer |
Key-features | Lesion/nodule segmentation, lesion/nodule classification, auto-population of lesion/nodule descriptors, AI independent risk assessment, alignment to diagnostic classification systems |
Suggested use | During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand), report suggestion After: diagnosis verification |
Data characteristics | |
Population | Adult (>= 22 years) female patients with soft tissue breast lesions and/or adult (>= 22 years) patients with thyroid nodules suspicious for cancer. |
Input | 2 orthogonal still ultrasound views of either breast lesions or thyroid nodules |
Input format | DICOM |
Output | BI-RADS/TI-RADS Categorization and Classifiers, Shape, Orientation, Confidence Level Indicator, Position, Size |
Output format | DICOM Secondary Capture and/or DICOM Structured Report, DICOM Client such as a scanner, selected PACS integrations |
Technology | |
Integration | Integration in standard reading environment (PACS), Integration CIS (Clinical Information System), Stand-alone third party application, Stand-alone webbased |
Deployment | Locally virtualized (virtual machine, docker) |
Trigger for analysis | Automatically, right after the image acquisition, On demand, triggered by a user through e.g. a button click, image upload, etc. |
Processing time | < 3 sec |
Certification | |
CE
|
Certified,
Class IIb
, MDR
|
FDA
|
510(k) cleared, Class II |
Market presence | |
On market since | 12-2021 |
Distribution channels | GE Healthcare, RMS Medical Devices, Amplify SDK, Alma AI MARKETPLACE |
Countries present (clinical, non-research use) | 25 |
Paying clinical customers (institutes) | >80 |
Research/test users (institutes) | >50 |
Pricing | |
Pricing model | Subscription |
Based on | Number of users, Number of analyses |
Evidence | |
Peer reviewed papers on performance |
|
Non-peer reviewed papers on performance |
|
Other relevant papers |